扩张型心肌病患者的表型聚类揭示重要病理生理差异
本研究对795例连续性扩张型心肌病(DCM)患者进行深度表型分析,基于无监督层次聚类识别出四个临床 distinct 的表型组:轻度收缩功能障碍、自身免疫、遗传与心律失常、严重收缩功能障碍。心脏RNA测序显示各组具有不同的分子谱,且无事件生存率存在差异。决策树模型用四个临床参数可在两个独立队列中复现分组,表明表型分组可行。
要点
- DCM可聚类为四个表型组:轻度收缩功能障碍、自身免疫、遗传与心律失常、严重收缩功能障碍。
- 各表型组具有不同的心脏转录组分子谱:促炎、促纤维化和代谢基因表达。
- 决策树用自身免疫病、EF、房颤和肾功能四个参数即可将患者分入四个表型组并对应结局。
核心结论
- 本研究识别出四个DCM表型组,其临床表现、分子谱和结局显著不同,为个性化治疗提供依据。
研究设计与样本
- 研究纳入马斯特里赫特心肌病注册的795例连续性DCM患者,进行深度表型分析,包括病因、合并症、影像和心内膜心肌活检。
- 基于主成分的无监督层次聚类识别表型组,并对91例心脏样本进行RNA测序。
- 决策树模型在西班牙(n=352)和意大利(n=437)两个独立DCM队列中验证分组可行性。
主要发现
- 四个表型组分别为:PG1轻度收缩功能障碍、PG2自身免疫、PG3遗传与心律失常、PG4严重收缩功能障碍。
- RNA测序显示PG2富集促炎基因表达,PG3富集促纤维化基因表达,PG4富集代谢基因表达。
- 四个表型组的无事件生存率存在差异,校正已知临床预测因素后仍显著。
- 决策树模型用自身免疫病、EF、房颤和肾功能四个临床参数可将患者分入四个表型组并对应结局。
临床怎么用
- 临床可基于自身免疫病、EF、房颤和肾功能四个参数对DCM患者进行表型分组,辅助风险分层和个体化治疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: The dilated cardiomyopathy (DCM) phenotype is the result of combined genetic and acquired triggers. Until now, clinical decision-making in DCM has mainly been based on ejection fraction (EF) and NYHA classification, not considering the DCM heterogenicity. The present study aimed to identify patient subgroups by phenotypic clustering integrating aetiologies, comorbidities, and cardiac function along cardiac transcript levels, to unveil pathophysiological differences between DCM subgroups. METHODS AND RESULTS: We included 795 consecutive DCM patients from the Maastricht Cardiomyopathy Registry who underwent in-depth phenotyping, comprising extensive clinical data on aetiology and comorbodities, imaging and endomyocardial biopsies. Four mutually exclusive and clinically distinct phenogroups (PG) were identified based upon unsupervised hierarchical clustering of principal components: [PG1] mild systolic dysfunction, [PG2] auto-immune, [PG3] genetic and arrhythmias, and [PG4] severe systolic dysfunction. RNA-sequencing of cardiac samples (n = 91) revealed a distinct underlying molecular profile per PG: pro-inflammatory (PG2, auto-immune), pro-fibrotic (PG3; arrhythmia), and metabolic (PG4, low EF) gene expression. Furthermore, event-free survival differed among the four phenogroups, also when corrected for well-known clinical predictors. Decision tree modelling identified four clinical parameters (auto-immune disease, EF, atrial fibrillation, and kidney function) by which every DCM patient from two independent DCM cohorts could be placed in one of the four phenogroups with corresponding outcome (n = 789; Spain, n = 352 and Italy, n = 437), showing a feasible applicability of the phenogrouping. CONCLUSION: The present study identified four different DCM phenogroups associated with significant differences in clinical presentation, underlying molecular profiles and outcome, paving the way for a more personalized treatment approach.
引用
- Verdonschot JAJ, Merlo M, Dominguez F, et al. Phenotypic clustering of dilated cardiomyopathy patients highlights important pathophysiological differences. Eur Heart J. 2021. PMID: 33156912. doi:10.1093/eurheartj/ehaa841
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。